SifrimD, ZerbibF: Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut, 2012; 61:1340–1354.
2.
DellonES, ShaheenNJ: Persistent reflux symptoms in the proton pump inhibitor era: The changing face of gastroesophageal reflux disease. Gastroenterology, 2010; 139:7–13.e3.
3.
RackoffA, AgrawalA, HilaA, et al.: Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus, 2005; 18:370–373.
4.
Abdul--HusseinM, FreemanJ, CastellD: Concomitant administration of a histamine2 receptor antagonist and proton pump inhibitor enhances gastric acid suppression. Pharmacotherapy, 2015; 35:1124–1129.
5.
ReimerC, NgB, SmithG, et al.: Concentrated alginate as add-on therapy in gastro-esophageal reflux disease patients with inadequate response to once daily proton pump inhibitor: A multicenter, randomized, double-blind, placebo-controlled pilot study. Gastroenterology, 2015; 148:S135–S136.
6.
RohofWO, BenninkRJ, SmoutAJ, et al.: An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol, 2013; 11:1585–1591.
7.
Surdea-BlagaT, Băncilă I, Dobru D, et al.: Mucosal protective compounds in the treatment of gastroesophageal reflux disease. A position paper based on evidence of the Romanian Society of Gastroenterology. J Gastrointest Liver Dis, 2016; 25:537–546.
8.
LiS, ShiS, ChenF, LinJ: The effects of baclofen for the treatment of gastroesophageal reflux disease: A meta-analysis of randomized controlled trials. Gastroenterol Res Pract, 2014; 2014:307–805.
9.
RichterJE, SabesinSM, KogutDG, et al.: Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 1996; 91:1766–1772.
10.
ViazisN, KeyoglouA, KanellopoulosAK, et al.: Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: A randomized- double-blind, placebo-controlled study. Amer J Gastroenterol, 2012; 107:1662–1667.
11.
OstovanehMR, SaeidiB, HajifathalianK, et al.: Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial. Neurogastroent Motil, 2014; 26:670–678.
12.
ClouseRE, LustmanPJ, EckertTC, et al.: Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: A double-blind, placebo controlled trial. Gastroenterolgy, 1987; 92:1027–1036.
13.
KaltenbachT, CrockettS, GersonLB: Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med, 2006; 166:965–971.
14.
KatzPO, GersonLB, VelaMF: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol, 2013; 108:308.
15.
JungDH, ParkH: Is Gastroesophageal reflux disease and achalasia coincident or not?. J Neurogastroenterol Motil, 2017; 23:5–8.
16.
FarrellB, PottieK, ThompsonW, et al.: Deprescribing proton pump inhibitors. Evidence-based clinical practice guideline. Can Fam Physician, 2017; 63:354–364.
